Cancer Biopsies Market Size
| Study Period | 2024 - 2029 |
| Market Size (2024) | USD 29.93 Billion |
| Market Size (2029) | USD 51.48 Billion |
| CAGR (2024 - 2029) | 11.46 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Cancer Biopsies Market Analysis
The Cancer Biopsies Market size is estimated at USD 29.93 billion in 2024, and is expected to reach USD 51.48 billion by 2029, growing at a CAGR of 11.46% during the forecast period (2024-2029).
The emergence of COVID-19 had a significant impact on the cancer biopsies market. During the initial phase of the pandemic, due to social distancing measures, hospital visits were drastically reduced, and only patients with emergencies were allowed. Thus, there was a decrease in cancer biopsies in 2020, which adversely impacted the market's growth. However, the adoption of new technologies increased post the pandemic, creating created new opportunities for the studied market.Liquid biopsies gained demand for detecting genetic alterations in cancer patients during the later phases of the pandemic. As per an article published in the PMC Journal in September 2021, the researchers recommended performing liquid biopsies, which represented a valid and less time-consuming diagnostic approach for managing lung cancer patients during the COVID-19 period than conventional tissue and cytological specimens. Hence, there was high demand for advanced technologies, which fueled the market's growth.
Factors such as the rising burden of oncology diseases, increasing adoption of liquid biopsies, advancement in technologies, and rising awareness of inherited oncology disorders and genetic testing are expected to contribute to the growth of the studied market.
The rise in cancer cases is also playing a key role in the cancer biopsies market's growth. According to CanRehab-2022, new cancer cases are expected to grow to 27.5 million by 2040, globally. According to the National Cancer Institute (NCI) 2022 update, there were around 83,730 new bladder cancer cases reported in 2021 in the United States, along with 284,200 breast cancer cases and 149,500 colon and rectal cancer cases. These figures indicate a huge burden of cancer among the population, acting as a potential elevating factor for the cancer biopsies market's growth.
The technological advancements and product launches by key players are also contributing to the growth of the market. For instance, in July 2022, BillionToOne Inc. launched its first oncology liquid biopsy product, Northstar Select and Northstar Response. The products are currently available for research use with selected academic cancer centers.
However, risks associated with biopsy procedures are expected to restrain the market's growth over the forecast period.
Cancer Biopsies Market Trends
This section covers the major market trends shaping the Cancer Biopsies Market according to our research experts:
Breast Cancer Segment is Expected to Grow During the Forecast Period
The breast cancer segment is expected to witness significant growth over the forecast period, largely attributed to the rising burden of breast cancer.
For instance, according to Breastcancer.org 2022 update, an estimated 287,850 new cases of invasive breast cancer were to be diagnosed in US women in 2022, along with 51,400 new cases of non-invasive (in situ) breast cancer. According to the American Society of Clinical Oncology (ASCO) January 2022 update, there are more than 3.8 million women in the United States with a history of breast cancer, inclduing women currently being treated and those who have completed their treatment.
According to 2021 statistics published by Breast Cancer Now, about 55,000 women are diagnosed with breast cancer in the United Kingdom every year. As per the same source above, 46,000 people are diagnosed with breast cancer in England every year, followed by 4,700 in Scotland, 2,800 in Wales, and 1,500 in Northern Ireland. Thus, the high burden of breast cancer cases across the world is expected to increase the diagnosis and biopsies testing, thus accelerating the segment's growth over the forecast period.
According to the January 2022 update of the American Cancer Society (ACS), the application of biopsies for breast cancer detection is increasing, and most often, a core-needle biopsy is performed rather than a surgical biopsy. Thus, the increased application of cancer biopsies for breast cancer is fueling the segment's growth.
North America is Anticipated to Witness Growth During the Forecast Period
The North American region held the largest share and is expected to maintain the same over the forecast period. Technological advancements, a high burden of cancer prevalence, and an increase in product approval and launches are major factors attributed to the market's growth.
There is a burden of cancer across the countries in North America. According to the NIH data published in March 2022, HER-2 negative cancer accounted for around 15-20% of the total breast cancer cases across the United States in 2021, and an estimated 287,850 new cases of female breast cancer were to be diagnosed in 2022.
In addition, according to the March 2022 update by the Government of Canada, breast cancer is Canada's second most frequent cancer, and 1 in every 8 women is likely to be diagnosed with breast cancer in the country. Thus, the growing prevalence of cancer across different nations in the region is expected to propel the demand for cancer biopsies, further fueling the market's growth over the forecast period.
Product innovations by major players and research institutes are also contributing to the market's growth. For instance, in June 2022, UCF researchers developed a liquid biopsy technique to help detect metastatic cancer in blood. It could help patients suffering from breast and lung cancers better monitor their disease. Thus, such developments are anticipated to contribute to the market's growth.
Cancer Biopsies Industry Overview
The cancer biopsies market is moderately competitive. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of cancer diseases, many regional players are expected to be a part of the cancer biopsies market over the forecast period. Some of the major players in the market are QIAGEN NV, Illumina Inc., Becton, Dickinson and Company, Myriad Genetics, and Thermo Fisher Scientific.
Cancer Biopsies Market Leaders
-
Illumina, Inc.
-
Becton, Dickinson and Company
-
Myriad Genetics
-
Thermo Fisher Scientific
-
QIAGEN
*Disclaimer: Major Players sorted in no particular order
Cancer Biopsies Market News
- In August 2022, Guardant Health gained US FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic (CDx) to choose patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC) with tumors that have activating HER2 (ERBB2) mutations for treatment with ENHERTU (fam-trastuzumab deruxtecan-nxki).
- In May 2022, Delfi Diagnostics, a developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, presented multiple applications for its next-generation liquid biopsy platform. Delfi presented a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection.
Cancer Biopsies Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Oncology Disorders and Increase in Adoption of Liquid Biopsies
- 4.2.2 Advancement in Technologies
- 4.2.3 Rising Awareness on Inherited Oncology Disorders and Genetic Testing
-
4.3 Market Restraints
- 4.3.1 Associated Risks with Biopsy Procedures
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Instruments
- 5.1.2 Kits and Consumables
- 5.1.3 Services
-
5.2 By Type
- 5.2.1 Tissue Biopsy
- 5.2.2 Surgical Biopsy
- 5.2.3 Liquid Biopsy
- 5.2.4 Other Types
-
5.3 By Application
- 5.3.1 Breast Cancer
- 5.3.2 Colorectal Cancer
- 5.3.3 Cervical Cancers
- 5.3.4 Lung Cancers
- 5.3.5 Other Applications
-
5.4 By End User
- 5.4.1 Hospitals
- 5.4.2 Diagnostic Laboratories
- 5.4.3 Other End Users
-
5.5 By Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 QIAGEN
- 6.1.2 Illumina Inc.
- 6.1.3 Becton, Dickinson and Company
- 6.1.4 Myriad Genetics Inc.
- 6.1.5 Thermo Fisher Scientific
- 6.1.6 BIOCEPT INC.
- 6.1.7 ANGLE PLC
- 6.1.8 Hologic Inc.
- 6.1.9 Lucence Diagnostics Pte. Ltd
- 6.1.10 Danaher Corporation
- 6.1.11 MDx Health
- 6.1.12 Agilent Technologies Inc.
- 6.1.13 Sysmex Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCancer Biopsies Industry Segmentation
As per the scope of the report, a cancer biopsy is a medical test in which a tissue or cells of the affected patient is taken to discover the presence, cause, or extent of cancer diseases affecting the patient.
The cancer biopsies market is segmented by product (instrument, kits and consumables, and services), type (tissue biopsy, surgical biopsy, liquid biopsy, and other types), application (breast cancer, colorectal cancer, cervical cancers, lung cancers, and other applications), end user (hospitals, diagnostics laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product | Instruments | |
| Kits and Consumables | ||
| Services | ||
| By Type | Tissue Biopsy | |
| Surgical Biopsy | ||
| Liquid Biopsy | ||
| Other Types | ||
| By Application | Breast Cancer | |
| Colorectal Cancer | ||
| Cervical Cancers | ||
| Lung Cancers | ||
| Other Applications | ||
| By End User | Hospitals | |
| Diagnostic Laboratories | ||
| Other End Users | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Cancer Biopsies Market Research FAQs
How big is the Cancer Biopsies Market?
The Cancer Biopsies Market size is expected to reach USD 29.93 billion in 2024 and grow at a CAGR of 11.46% to reach USD 51.48 billion by 2029.
What is the current Cancer Biopsies Market size?
In 2024, the Cancer Biopsies Market size is expected to reach USD 29.93 billion.
Who are the key players in Cancer Biopsies Market?
Illumina, Inc., Becton, Dickinson and Company, Myriad Genetics, Thermo Fisher Scientific and QIAGEN are the major companies operating in the Cancer Biopsies Market.
Which is the fastest growing region in Cancer Biopsies Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cancer Biopsies Market?
In 2024, the North America accounts for the largest market share in Cancer Biopsies Market.
What years does this Cancer Biopsies Market cover, and what was the market size in 2023?
In 2023, the Cancer Biopsies Market size was estimated at USD 26.85 billion. The report covers the Cancer Biopsies Market historical market size for years: . The report also forecasts the Cancer Biopsies Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cancer Biopsy Industry Report
Statistics for the 2024 Cancer Biopsy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cancer Biopsy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
